Response-guided neoadjuvant chemo beneficial in breast CA

Response-guided neoadjuvant chemo beneficial in breast CA
For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.

(HealthDay)—For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.

Gunter von Minckwitz, M.D., from the Institute for Pathology in Berlin, and colleagues examined disease-free survival (DFS) and overall survival (OS) among patients with early breast cancer after treatment with response-guided neoadjuvant chemotherapy. A total of 2,072 patients were treated with two cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC). Responders were randomized to four or six additional TAC cycles (704 and 686 patients, respectively), while early non-responders were assigned to four cycles of TAC (321) or vinorelbine and capecitabine (NX; 301 patients) before surgery.

The researchers found that DFS was significantly longer for early responders assigned to eight sessions of TAC versus six sessions (hazard ratio [HR], 0.78) and in early non-responders receiving TAC-NX versus six sessions of TAC (HR, 0.59). Compared with conventional chemotherapy (six sessions of TAC), response-guided therapy (eight sessions of TAC or TAC-NX) correlated with significantly longer DFS (HR, 0.71) and OS (HR, 0.79) in exploratory analysis. In all hormone receptor-positive tumors, but not hormone receptor-negative tumors, DFS was longer after response-guided chemotherapy.

"This exploratory analysis suggests that response-guided might improve survival and is most effective in -positive tumors," the authors write. "If confirmed, the response-guided approach could provide a clinically meaningful advantage for the neoadjuvant over the adjuvant approach in early ."

Several authors disclosed to pharmaceutical companies, including Amgen, Chugai, Roche, and sanofi-aventis, all of which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Smoking worsens outcomes with advanced colon cancer

date Apr 06, 2013

(HealthDay)—Smoking is tied to significantly shorter disease-free survival (DFS) and time to recurrence (TTR) in patients undergoing treatment for stage III colon cancer, according to a study published ...

Recommended for you

HLA expression tied to penile cancer outcomes

date 5 hours ago

(HealthDay)—Human leukocyte antigen (HLA) expression appears to be tied to clinical outcomes in penile cancer, according to a study published in the April issue of The Journal of Urology.

Study points to potential new lung cancer therapy

date 5 hours ago

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.